Kurve Therapeutics

Kurve Therapeutics

Growth Stage

Bypassing the Blood-Brain Barrier

Bypassing the Blood-Brain Barrier

Overview

Funding data not publicly available
Platform

Rialto Markets

Start Date

08/02/2022

Close Date

Not Provided

Min. Goal
$580
Max. Goal
$50,000,000
Min. Investment

$580

Security Type

Equity - Common

Series

Series A

SEC Filing Type

RegA+    Open SEC Filing

Price Per Share

$5.80

Pre-Money Valuation

$291,787,299

Year Founded

2019

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Lynnwood, Washington

Business Type

Growth

Kurve Therapeutics is raising funds through Reg A+ crowdfunding with Rialto Markets as the Broker-Dealer. The company has developed its patented Controlled Particle Dispersion (CPD) intranasal drug delivery technology. The technology creates a focused flow through the curved pathways of the nasal cavity and allows access to the olfactory region to treat neurogenerative diseases. Kurve Therapeutics’ technology has been featured in multiple publications and has completed Phase II studies on Alzheimer’s patients. Marc Giroux, Tom McDowell, and Glenn Cornett founded Kurve Therapeutics in 2019. The current crowdfunding campaign has a maximum target of $50,000,000. The campaign proceeds will be used for asset purchase, marketing, clinical studies, contract manufacturing, and working capital.

Balance Sheet

Cash and Cash Equivalents

$373,804

Accounts and Notes Receivable

$15,000

Total Assets

$640,574

Accounts Payable & Accrued Liabilities

$28,331

Long Term Debt

$507,500

Total Liabilities

$606,726

Total Stockholders' Equity

$33,848

Total Liabilities and Equity

$640,574

Statement of Comprehensive Income Information

Total Revenues

$70,700

Costs & Expenses Applicable to Rev

$128,344

Net Income

$-65,427

Earnings Per Share - Basic

$0.00

Earnings Per Share - Diluted

$0.00

Auditor: Assurance Dimensions
Financials as of: 08/02/2022
Create a free account today to gain access to KingsCrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article

No company has been able to develop an FDA-approved treatment that stops Alzheimer’s in its tracks. Kurve Therapeutics has the potential to change that with its potentially groundbreaking device. But its long road to FDA approval and its inexperienced team may threaten the company’s survival.

Founder Profile

Kurve Therapeutics Founder Marc Giroux on Treating Alzheimer’s and More

The central nervous system (CNS) disorder umbrella houses a number of familiar names, like Alzheimer’s, Parkinson’s, and multiple sclerosis. These conditions are often life-altering to sufferers, and many are incurable. Thankfully, treatments are available, and scientists aren’t done looking for new solutions.

Kurve Therapeutics is fighting CNS disorders right up the nose with its patented Controlled Particle Dispersion technology. This intranasal technology delivers drugs noninvasively and painlessly, and it makes treatments more precise and effective. We reached out to founder and CEO Marc Giroux to hear about why he originally started working on the technology and how Kurve Therapeutics overcame assumptions.

Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.

Read Founder Interview

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Kurve Therapeutics on Rialto Markets 2022
Platform: Rialto Markets
Security Type: Equity - Common
Valuation: $291,787,299
Price per Share: $5.80

Follow company

Follow Kurve Therapeutics on Rialto Markets 2022

Buy Kurve Therapeutics's Deal Report

Warning: according to the close date for this deal, Kurve Therapeutics may no longer be accepting investments.

Kurve Therapeutics Deal Report

Get KingsCrowd’s comprehensive report on Kurve Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Kurve Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the Kurve Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge